ClearPoint Neuro CEO settles RSUs, pays taxes

ClearPoint Neuro CEO Joseph Burnett reported routine equity compensation activity.

Rhea-AI Filing Summary

ClearPoint Neuro CEO Joseph Burnett reported routine equity compensation activity. On March 6, 2026, 47,407 restricted stock units converted into the same number of shares of common stock at a stated price of $0.00 per share, reflecting scheduled vesting.

To cover tax obligations from this vesting, 22,709 common shares were delivered back to ClearPoint Neuro at $10.00 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Burnett directly holds 54,232 common shares and indirectly holds 193,231 common shares through the Joseph M. Burnett Trust dated October 20, 2022.

Insider Trade Summary

47,407 shares exercised/converted

Exercise 4 txns

Insider BURNETT JOSEPH

Role CEO and President

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	47,407	$0.00	$0.00
Exercise	Common Stock	47,407	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	22,709	$10.00	$227K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 54,232 shares (Direct); Common Stock — 193,231 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
3. F3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ClearPoint Neuro (CLPT) CEO report on this Form 4?

Joseph Burnett reported vesting of restricted stock units and related tax withholding. 47,407 RSUs settled into common shares, and 22,709 of those shares were delivered to ClearPoint Neuro to satisfy tax obligations, with no open-market purchase or sale activity disclosed.

How many ClearPoint Neuro (CLPT) restricted stock units vested for CEO Joseph Burnett?

47,407 restricted stock units vested for Joseph Burnett. Each RSU represented a contingent right to receive one share of ClearPoint Neuro common stock, and the units settled into the same number of shares on their scheduled vesting date as part of his equity compensation.

How many ClearPoint Neuro (CLPT) shares were used to pay taxes in this Form 4?

22,709 ClearPoint Neuro common shares were delivered to cover tax withholding. These shares, valued at $10.00 per share, were transferred back to the company to satisfy tax obligations arising from the vesting of restricted stock, rather than being sold in the open market.

How many ClearPoint Neuro (CLPT) shares does the CEO hold after this transaction?

Joseph Burnett directly holds 54,232 ClearPoint Neuro common shares after the transaction. In addition, he indirectly holds 193,231 shares through the Joseph M. Burnett Trust dated October 20, 2022, where he serves as trustee with beneficial ownership.

Does this ClearPoint Neuro (CLPT) Form 4 show any open-market stock sales by the CEO?

The filing does not show any open-market stock sales by Joseph Burnett. The only disposition is a tax-withholding transfer of 22,709 shares back to ClearPoint Neuro to satisfy tax obligations related to restricted stock vesting, not a discretionary market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		M		47,407	A	(1)	76,941	D
Common Stock	03/06/2026		F		22,709(2)	D	$10	54,232	D
Common Stock								193,231	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/06/2026		M			47,407	(1)	(1)	Common Stock	47,407	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.